

## Monday, February 12, 2018

- 6:30 p.m.-8:15 p.m.**                    **WELCOME AND KEYNOTE LECTURES**  
Legends I-IV
- 6:30 p.m.-6:45 p.m.                **Welcome**  
Conference Cochairs
- 6:45 p.m.-7:30 p.m.                **Differential regulation of inflammation in the brain and spinal cord**  
Joan M. Goverman, University of Washington, Seattle, WA
- 7:30 p.m.-8:15 p.m.                **Systemic immune therapies for treating brain metastasis and their effects on the tumor microenvironment in the brain**  
Harriet M. Kluger, Yale University, New Haven, CT
- 8:30 p.m.-10:00 p.m.**            **OPENING RECEPTION**  
Legends V-VI

## Tuesday, February 13, 2018

### Basic Insights into Immune Mechanisms of CNS that Could Be Relevant to Unique CNS Tumor Environment

- 7:00 a.m.-8:00 a.m.**                **CONTINENTAL BREAKFAST**  
Encore
- 8:00 a.m.-10:00 a.m.**            **PLENARY SESSION 1: PRINCIPLES THAT GOVERN UNIQUE ASPECTS OF THE HOST IMMUNE RESPONSE WITHIN THE BRAIN**  
Legends I-IV  
**Session Chair: Glenn F. Rall**, Fox Chase Cancer Center, Philadelphia, PA
- 8:00 a.m.-8:30 a.m.                **CNS-draining lymphatics in regulation of meningeal immunity**  
Antoine Louveau, University of Virginia School of Medicine, Charlottesville, VA
- 8:30 a.m.-9:00 a.m.                **Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment**  
Aaron Diaz, University of California San Francisco, San Francisco, CA
- 9:00 a.m.-9:30 a.m.                **Modeling cerebral edema in immunotherapy recipients**  
Glenn F. Rall
- 9:30 a.m.-9:45 a.m.                **Integrated omics analysis of temporal changes of neoantigen and tumor microenvironment in primary and recurrent gliomas\***  
Takahide Nejo, Department of Neurosurgery, The University of Tokyo, Tokyo, Japan
- 9:45 a.m.-10:00 a.m.            **Contraction of T-cell richness in brain metastases of non-small cell lung cancers\***  
Aaron Mansfield, Mayo Clinic, Rochester, MN

*\*Short talk from proffered abstract*

# CONFERENCE PROGRAM

<b>10:00 a.m.-10:30 a.m.</b>	<b>BREAK</b> Abbey Road
<b>10:30 a.m.-12:30 p.m.</b>	<b>PLENARY SESSION 2: CNS IMMUNOLOGY: EFFECTOR MECHANISM (THE EFFERENT ARM OF CNS IMMUNITY)</b> Legends I-IV <b>Session Chair: Robyn S. Klein</b> , Washington University School of Medicine, St. Louis, MO
10:30 a.m.-11:00 a.m.	<b>Innate immune regulation of blood-brain barrier function</b> Robyn S. Klein
11:00 a.m.-11:30 a.m.	<b>Regulatory programs mediated by lectins and glycans in CNS immunopathology</b> Gabriel A. Rabinovich, Instituto de Biología y Medicina Experimental, CONICET, Buenos Aires, Argentina
11:30 a.m.-12:00 p.m.	<b>Microglial responses at the blood-brain barrier</b> Dimitrios Davalos, Cleveland Clinic Lerner Research Institute, Cleveland, OH
12:00 p.m.-12:15 p.m.	<b>Intravital imaging of CAR-T cells directed against GD2 in a preclinical immunocompetent glioblastoma model*</b> Surya Murty, Stanford University, Stanford, CA
12:15 p.m.-12:30 p.m.	<b>Adoptive cell therapy for high-grade gliomas using simultaneous temozolomide and intracranial MGMT-modified <math>\gamma\delta</math> T cells following standard post-resection chemo and radiotherapy*</b> Lawrence Lamb, University of Alabama at Birmingham, Birmingham, AL
<b>12:30 p.m.-3:15 p.m.</b>	<b>POSTER SESSION A / LUNCH</b> Legends V-VI / Encore
<b>3:15 p.m.-5:45 p.m.</b>	<b>PLENARY SESSION 3: THE CNS TUMOR MICROENVIRONMENT</b> Legends I-IV <b>Session Chair: Hideho Okada</b> , UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
3:15 p.m.-3:45 p.m.	<b>Gliomas: Big data visualization and mouse modeling</b> Eric C. Holland, Fred Hutchinson Cancer Research Center, Seattle, WA
3:45 p.m.-4:15 p.m.	<b>Sex-specific modifiers of brain tumor risk</b> Joshua B. Rubin, Washington University School of Medicine, McDonnell Genome Institute, St. Louis, MO
4:15 p.m.-4:45 p.m.	<b>Immunopathology of brain tumors: Relevance of immune infiltrates</b> Christel Herold-Mende, University of Heidelberg, Heidelberg, Germany
4:45 p.m.-5:15 p.m.	<b>Neoantigens and mutation-induced immunoregulatory mechanisms in gliomas</b> Hideho Okada
5:15 p.m.-5:30 p.m.	<b>Discrimination of response to CAR T-cell therapy using a novel response metric incorporating tumor growth kinetics in recurrent GBM patients*</b> Gustavo De Leon, Mayo Clinic, Phoenix, AZ

*\*Short talk from proffered abstract*

# CONFERENCE PROGRAM

5:30 p.m.-5:45 p.m. **Vascular niche regulates alternative macrophage activation in glioblastoma immunity\***  
Yi Fan, University of Pennsylvania, Philadelphia, PA

**DINNER ON OWN / EVENING OFF**

## Wednesday, February 14, 2018

### Brain Metastasis and Enhancing Immune Responses to CNS Malignancies

**7:00 a.m.-8:00 a.m. CONTINENTAL BREAKFAST**  
Encore

**8:00 a.m.-10:00 a.m. PLENARY SESSION 4: CNS METASTASIS**  
Legends I-IV  
**Session Chair: Patricia S. Steeg**, National Cancer Institute, Bethesda, MD

8:00 a.m.-8:30 a.m. **What is the status of blood-tumor barrier and immune cells in brain met models?**  
Patricia S. Steeg

8:30 a.m.-9:00 a.m. **Innate immunity in parenchymal and leptomeningeal metastasis: Mechanism and therapeutic opportunities**  
Adrienne A. Boire, Memorial Sloan Kettering Cancer Center, New York, NY

9:00 a.m.-9:30 a.m. **The inflammatory microenvironment in brain metastases as a therapeutic target**  
Anna Sophie Berghoff, Medical University of Vienna, Vienna, Austria

9:30 a.m.-9:45 a.m. **Syndecan 1/IL-8 axis facilitates breast cancer brain metastasis through modulation of blood-brain barrier permeability\***  
Sierra Mosticone Wangenstein, Virginia Commonwealth University, Richmond, VA

9:45 a.m.-10:00 a.m. **Ligand-independent EphA2 signaling drives an amoeboid melanoma phenotype that metastasizes to the brain\***  
Inna Smalley, The Moffitt Cancer Center & Research Institute, Tampa, FL

**10:00 a.m.-10:30 a.m. BREAK**  
Abbey Road

*\*Short talk from proffered abstract*

# CONFERENCE PROGRAM

- 10:30 a.m.-12:30 p.m.**      **PLENARY SESSION 5: CHECKPOINT PATHWAYS RELEVANT TO CNS**  
Legends I-IV  
**Session Chair: Robert M. Prins**, David Geffen School of Medicine at UCLA,  
Los Angeles, CA
- 10:30 a.m.-11:00 a.m.      **Challenges in testing immunotherapies in clinical trials**  
Mark R. Gilbert, NCI-CCR, Bethesda, MD
- 11:00 a.m.-11:30 a.m.      **Immune checkpoint biomarkers in CNS gliomas and metastasis**  
Amy B. Heimberger, The University of Texas MD Anderson Cancer Center, Houston, TX
- 11:30 a.m.-12:00 p.m.      **Immune checkpoint blockade in patients with melanoma metastatic to the brain**  
Kim A. Margolin, City of Hope, Duarte, CA
- 12:00 p.m.-12:15 p.m.      **Influence of PD-1 antibody blockade on the tumor microenvironment in patients with recurrent glioblastoma\***  
Aaron Mochizuki, University of California Los Angeles, Los Angeles, CA
- 12:15 p.m.-12:30 p.m.      **The immune landscape of PD-1 expression in human glioblastoma\***  
Alexander Lee, University of California Los Angeles, Los Angeles, CA
- 12:30 p.m.-3:15 p.m.**      **POSTER SESSION B / LUNCH**  
Legends V-VI / Encore
- 3:15 p.m.-5:30 p.m.**      **PLENARY SESSION 6: ADOPTIVE T-CELL THERAPY FOR CNS MALIGNANCIES**  
Legends I-IV  
**Session Chair: Christine Brown**, City of Hope, Duarte, CA
- 3:15 p.m.-3:45 p.m.      **Adoptively transferred T cells for primary and secondary CNS malignancies**  
Richard M. Sherry, National Cancer Institute, Bethesda, MD
- 3:45 p.m.-4:15 p.m.      **CAR T cell immunotherapy of brain tumors and associated neurotoxicities**  
Michael C. Jensen, Seattle Children's Research Institute, Seattle, WA
- 4:15 p.m.-4:45 p.m.      **Neurotoxicity observed in CD19 CAR therapy**  
Hyam I. Levitsky, Juno Therapeutics, Seattle, WA  
*(not eligible for CME credit)*
- 4:45 p.m.-5:00 p.m.      **New therapeutic approach for central nervous system lymphoma by CD19 CAR T cells\***  
Xiuli Wang, City of Hope National Medical Center, Duarte, CA
- 5:00 p.m.-5:15 p.m.      **Cloning and characterization of T-cell receptors reactive to the mutant isocitrate dehydrogenase-1-derived neopeptide in low-grade gliomas\***  
Payal Watchmaker, Department of Neurological Surgery, University of California San Francisco, San Francisco, CA
- 5:15 p.m.-5:30 p.m.      **Co-stimulatory domain 41BB (CD137) improves specificity and proliferative potential of IL13Ra2-specific CAR T cells for the treatment of glioblastoma\***  
Renate Starr, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA

## DINNER ON OWN / EVENING OFF

\*Short talk from proffered abstract

## Thursday, February 15, 2018

### Multimodality Approaches

<b>7:00 a.m.-8:00 a.m.</b>	<b>CONTINENTAL BREAKFAST</b> Encore
<b>8:00 a.m.-10:00 a.m.</b>	<b>PLENARY SESSION 7: VIRAL THERAPY</b> Legends I-IV <b>Session Chair: Noriyuki Kasahara</b> , University of Miami Health System, Miami, FL
8:00 a.m.-8:30 a.m.	<b>Oncolytic poliovirus immunotherapy</b> Matthias Gromeier, Duke University Medical Center, Durham, NC
8:30 a.m.-9:00 a.m.	<b>Oncolytic adenovirus: The immune angle</b> Juan Fueyo, The University of Texas MD Anderson Cancer Center, Houston, TX
9:00 a.m.-9:15 a.m.	<b>An oncolytic measles virus-sensitive group 3 medulloblastoma model in immune-competent mice*</b> Sangeet Lal, University of California San Francisco, San Francisco, CA
9:15 a.m.-9:45 a.m.	<b>Retroviral replicating vectors for tumor-targeted gene therapy and immunotherapy of glioma</b> Noriyuki Kasahara
9:45 a.m.-10:00 a.m.	<b>Immunologic activation in recurrent high-grade glioma patients with durable complete response following treatment with Toca 511 and Toca FC*</b> Clark Chen, University of Minnesota, Minneapolis, MN
<b>10:00 a.m.-10:15 a.m.</b>	<b>BREAK</b> Abbey Road
<b>10:15 a.m.-12:15 p.m.</b>	<b>PLENARY SESSION 8: MULTIMODALITY IMMUNOTHERAPY APPROACHES TARGETING CNS TUMOR MICROENVIRONMENT</b> Legends I-IV <b>Session Chair: Ignacio Melero</b> , University of Navarra, Pamplona, Spain
10:15 a.m.-10:45 a.m.	<b>Radiation therapy and PD-1 blockade in brain metastasis from breast cancer</b> Silvia C. Formenti, Weill Cornell Medical College, New York, NY
10:45 a.m.-11:15 a.m.	<b>Targeted and immunotherapeutic approaches in brain metastases</b> Frank A. Winkler, German Cancer Research Center, Heidelberg, Germany
11:15 a.m.-11:45 a.m.	<b>Novel combinations: Neoadjuvant presurgery and dendritic cell vaccine for glioblastoma</b> Ignacio Melero

*\*Short talk from proffered abstract*

# CONFERENCE PROGRAM

- 11:45 a.m.-12:00 p.m.      **IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma\***  
Derek Wainwright, Northwestern University Feinberg School of Medicine, Chicago, IL
- 12:00 p.m.-12:15 p.m.      **Noninvasive monitoring of in situ immunotherapeutic responses in glioblastoma using novel PET and MRI techniques\***  
Joseph Antonios, University of California Los Angeles, Los Angeles, CA
- 12:15 p.m.-12:30 p.m.**      **CLOSING REMARKS**  
Legends I-IV  
Hideho Okada, UCSF Helen Diller Family Comprehensive Cancer Center,  
San Francisco, CA
- 12:30 p.m.**      **DEPARTURE**

*\*Short talk from proffered abstract*